An international team of researchers reports in the New England Journal of Medicine dramatically transforming aPAP treatment by helping develop a drug that patients can inhale once a day so their body will clear out the pulmonary waste.

Within 24 hours of the first dose of Silmitasertib the patient showed significant clinical improvement and the oxygen requirement was weaned to room air. The patient was discharged from the hospital five days after starting Silmitasertib.

The FDA expanded the emergency use authorization for the Pfizer messenger RNA Covid-19 vaccine for kids age 12–15 years old.

Do individuals get more protection against COVID-19 if they get their vaccinations and boosters in the same arm?